Results 31 to 40 of about 93,084 (311)

Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy. [PDF]

, 2014
BACKGROUND: Sarcomere protein mutations in hypertrophic cardiomyopathy induce subtle cardiac structural changes before the development of left ventricular hypertrophy (LVH).
Bassett, P, Bluemke, DA, Canter, CE, Captur, G, Day, SM, Elliott, PM, Esteban, MT, Ferreira, VM, Finocchiaro, G, Ho, CY, Li, C, Lopes, LR, McKenna, WJ, Mohun, TJ, Moon, JC, Muthurangu, V, Patel, V, Seidman, CE, Sherrid, MV   +18 more
core   +1 more source

Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Cardiogenic shock from most causes has unfavorable prognosis. Hypertrophic cardiomyopathy (HCM) can uncommonly present with apical ballooning and shock in association with sudden development of severe and unrelenting left ventricular (LV ...
Mark V. Sherrid, Daniel G. Swistel, Iacopo Olivotto, Maurizio Pieroni, Omar Wever‐Pinzon, Katherine Riedy, Richard G. Bach, Mustafa Husaini, Sharon Cresci, Alex Reyentovich, Daniele Massera, Martin S. Maron, Barry J. Maron, Bette Kim   +13 more
doaj   +1 more source

Probing Subcellular Nanostructure of Engineered Human Cardiomyocytes in 3D Tissue [PDF]

, 2021
The structural and functional maturation of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) is essential for application to pharmaceutical testing, disease modeling, and ultimately therapeutic use. Multicellular 3D-tissue platforms have improved functional maturation of hiPSC-CMs, but probing cardiac contractile properties ...
arxiv   +1 more source

Plasma Cardiac Troponin I Concentration and Cardiac Death in Cats with Hypertrophic Cardiomyopathy [PDF]

, 2014
BACKGROUND: The use of cardiac biomarkers to assist in the diagnosis of occult and symptomatic hypertrophic cardiomyopathy (HCM) in cats has been established. There is limited data describing their prognostic utility in cats with HCM.
Abbott, Atkins, Bang, Blume, Chan, Christiaans, Coats, Connolly, Connolly, Connolly, Fernandes, Fox, Fox, Fox, Gersh, Geske, Herndon, Humm, Kittleson, Kubo, Kubo, Langhorn, Lefbom, Lyons, Maron, Maron, Maron, Moreno, Ohno-Machado, Oyama, Paige, Payne, Payne, Peacock, Perna, Perna, Rush, Schober, Schober, Schober, Singletary, Trehiou-Sechi, Wagner, Wess   +43 more
core   +1 more source

Hypertrophic cardiomyopathy in athletes [PDF]

European Cardiology Review, 2017
The diagnosis of hypertrophic cardiomyopathy can be challenging in the athlete. A morphologically mild phenotype of the condition may mimic physiological left ventricular hypertrophy and requires careful evaluation of the athlete with an array of clinical tools.
Malhotra, Aneil, Sharma, Sanjay
openaire   +3 more sources

Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy. [PDF]

, 2012
Background The role of a tailored surgical approach for hypertrophic cardiomyopathy (HCM) on regional ventricular remodelling remains unknown. The aims of this study were to evaluate the pattern, extent and functional impact of regional ventricular ...
Cecchi, F, El Guindy, A, El-Hamamsy, I, Lekadir, K, Merrifield, R, Olivotto, I, Rega, L, Yacoub, MH, Yang, G   +8 more
core   +2 more sources

Feline Hypertrophic Cardiomyopathy: A Spontaneous Large Animal Model of Human HCM. [PDF]

, 2017
Hypertrophic cardiomyopathy (HCM) is a common disease in pet cats, affecting 10-15% of the pet cat population. The similarity to human HCM, the rapid progression of disease, and the defined and readily determined endpoints of feline HCM make it an ...
Freeman, Lisa M, Huggins, Gordon S, Maron, Martin S, Rush, John E, Stern, Joshua A   +4 more
core   +2 more sources

Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy

Journal of Nanobiotechnology, 2018
Background Theranostic perfluorocarbon nanoprobes have recently attracted attention due to their fascinating versatility in integrating diagnostics and therapeutics into a single system.
Xueli Zhao, Wen Luo, Jing Hu, Lei Zuo, Jing Wang, Rui Hu, Bo Wang, Lei Xu, Jing Li, Meng Wu, Pan Li, Liwen Liu   +11 more
doaj   +1 more source

Valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy: the design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial [PDF]

, 2017
Background: Hypertrophic cardiomyopathy (HCM) is often caused by sarcomere gene mutations, resulting in left ventricular hypertrophy (LVH), myocardial fibrosis, and increased risk of sudden cardiac death and heart failure.
Braunwald, Eugene, Cirino, Allison L., Colan, Steven D., Day, Sharlene M., Desai, Akshay S., Ho, Carolyn Y., Lipshultz, Steven E., MacRae, Calum A., McMurray, John J.V., Orav, E. John, Shi, Ling, Solomon, Scott D.   +11 more
core   +1 more source

Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Disopyramide is used to treat heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM) with known medium‐term efficacy and safety, while long‐term outcomes are unknown. Methods and Results A total of 92 consecutive
Daniele Massera, Mark V. Sherrid, Elizabeth Adlestein, Nadia Bokhari, Isabel C. Alvarez, Woon Y. Wu, Maria C. Reuter, Martin S. Maron, Barry J. Maron, Ethan J. Rowin   +9 more
doaj   +1 more source